Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02840279 · ClinicalTrials.gov registry record · Phase 1
A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects
A Phase 1 study, sponsored by Tetra Discovery Partners.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT02840279: Completed Phase 1 study, sponsored by Tetra Discovery Partners.
NCT02840279 is a Phase 1 study that has completed, run by Tetra Discovery Partners. The registered enrollment target is 77 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02840279, a Phase 1 study, has completed, sponsored by Tetra Discovery Partners.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
This is a randomized, double-blind (Investigator and subject-blinded) placebo-controlled, multiple, ascending-dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy young and elderly male and female subjects and to provide a preliminary assessment of the cognitive effects of BPN14770 in healthy elderly subjects.
Interventions
- DRUG Placebo
- DRUG BPN14770
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2016-06 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02840279
The ClinicalTrials.gov registry entry for NCT02840279 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tetra Discovery Partners, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02840279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02840279 about?
NCT02840279 is a clinical study titled "A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects". This is a randomized, double-blind (Investigator and subject-blinded) placebo-controlled, multiple, ascending-dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy young and elderly male and female subjects and to provide a preliminary assessment of the ...
What is the current status of trial NCT02840279?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2016-06. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02840279?
The interventions under investigation include: Placebo (DRUG), BPN14770 (DRUG).
Who is sponsoring clinical trial NCT02840279?
This trial is sponsored by Tetra Discovery Partners, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.